Showing 1 posts of 1 posts found.
EVerZom, a French biopharma company focused on exosome-based therapies, has announced it has received €3m in funding as part of …
NHS England approves delayed-release treatment for rare kidney disease
Product value to pathway impact: What the CVD Modern Service Framework means for pharma
Functional lung imaging offers new possibilities for respiratory care
Five Facts about cardiovascular disease
Data integrity: the keystone for AI adoption, patient safety and organisational reputation